(AOF) – Medesis Pharma announces the completion of a capital increase of 440,000 euros. The biotech developing drugs based on a proprietary technology for administering active ingredients in nano micelles via the oral route, specifies that this will include continuing the development of its phase 2 clinical study for the treatment of the disease. of Alzheimer’s. The resulting dilution is 11%. Following this operation, the capital of Medesis Pharma is made up of 4.96 million shares with a par value of 0.50 euros.
Medesis Pharma requested and obtained the opening, on September 29, 2023, of a safeguard procedure with the Montpellier Commercial Court. This can last up to twelve months and leads to the temporary suspension of its financial and tax obligations.
The cash flow as of June 30, 2023 amounted to 139,000 euros, and the resources resulting from this capital increase will allow Medesis Pharma to extend its cash flow horizon until the month of January 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.